Bruce C Baguley

List of Publications by Year
in descending order

263 papers	12,890 citations	23567 58 h-index	32842 100 g-index
268 all docs	268 docs citations	268 times ranked	12970 citing authors

#	Article	IF	Citations
1	Disrupting tumour blood vessels. Nature Reviews Cancer, 2005, 5, 423-435.	28.4	867
2	Signaling Pathways in Melanogenesis. International Journal of Molecular Sciences, 2016, 17, 1144.	4.1	605
3	Multiple Drug Resistance Mechanisms in Cancer. Molecular Biotechnology, 2010, 46, 308-316.	2.4	426
4	Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which may not act via topoisomerase II. Journal of Medicinal Chemistry, 1990, 33, 814-819.	6.4	284
5	Epigenetic regulation in human melanoma: past and future. Epigenetics, 2015, 10, 103-121.	2.7	237
6	Potential antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. Journal of Medicinal Chemistry, 1978, 21, 658-668.	6.4	200
7	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemotherapy and Pharmacology, 2000, 46, 343-350.	2.3	197
8	A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Analytical Biochemistry, 1984, 139, 272-277.	2.4	192
9	Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. Journal of Medicinal Chemistry, 1981, 24, 170-177.	6.4	188
10	Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. Journal of Medicinal Chemistry, 1991, 34, 217-222.	6.4	187
11	In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. Journal of Inorganic Biochemistry, 2008, 102, 303-310.	3.5	174
12	Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma. Cancer Discovery, 2014, 4, 1418-1429.	9.4	174
13	Antivascular therapy of cancer: DMXAA. Lancet Oncology, The, 2003, 4, 141-148.	10.7	167
14	The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Research, 1978, 5, 161-171.	14.5	151
15	Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. European Journal of Cancer & Clinical Oncology, 1991, 27, 482-487.	0.7	149
16	Structureâ^'Activity Relationships for Substituted Bis(acridine-4-carboxamides):â€‰ A New Class of Anticancer Agents. Journal of Medicinal Chemistry, 1999, 42, 2383-2393.	6.4	145
17	Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as minimal DNA-intercalating antitumor agents with in vivo solid tumor activity. Journal of Medicinal Chemistry, 1989, 32, 396-401.	6.4	143
18	Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles. Journal of Medicinal Chemistry, 1979, 22, 134-150.	6.4	142

#	Article	IF	Citations
19	Blood Flow Failure as a Major Determinant in the Antitumor Action of Flavone Acetic Acid. Journal of the National Cancer Institute, 1989, 81, 1005-1013.	6.3	141
20	DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol (Hoechst 33258). Journal of Medicinal Chemistry, 1994, 37, 4338-4345.	6.4	141
21	Disrupting established tumor blood vessels. Cancer, 2010, 116, 1859-1871.	4.1	138
22	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
23	Dual Topoisomerase I / II Inhibitors in Cancer Therapy. Current Topics in Medicinal Chemistry, 2003, 3, 339-353.	2.1	136
24	Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. Journal of Medicinal Chemistry, 1987, 30, 843-851.	6.4	126
25	Emerging Role of Long Non-Coding RNA SOX2OT in SOX2 Regulation in Breast Cancer. PLoS ONE, 2014, 9, e102140.	2.5	119
26	Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. Journal of Medicinal Chemistry, 1989, 32, 793-799.	6.4	118
27	Early stages of the apoptotic pathway in plant cells are reversible. Plant Journal, 1998, 13, 803-814.	5.7	115
28	Induction of tumour necrosis factor-? by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1995, 36, 143-148.	2.3	113
29	Synthesis and Antitumor Properties ofN-[2-(Dimethylamino)ethyl]carboxamide Derivatives of Fused Tetracyclic Quinolines and Quinoxalines:Â A New Class of Putative Topoisomerase Inhibitors. Journal of Medicinal Chemistry, 1997, 40, 2040-2046.	6.4	112
30	Potential antitumor agents. Part 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. Journal of Medicinal Chemistry, 1984, 27, 1481-1485.	6.4	109
31	Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. Journal of Medicinal Chemistry, 1988, 31, 707-712.	6.4	102
32	A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. Journal of Mathematical Biology, 2003, 47, 295-312.	1.9	100
33	Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International Journal of Pharmaceutics, 2009, 367, 179-186.	5.2	100
34	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Journal of Medicinal Chemistry, 2011, 54, 7105-7126.	6.4	97
35	Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. Journal of Medicinal Chemistry, 1985, 28, 1568-1574.	6.4	95
36	Bis(phenazine-1-carboxamides):Â Structureâ^'Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs. Journal of Medicinal Chemistry, 2000, 43, 1350-1358.	6.4	95

#	Article	IF	Citations
37	Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. European Journal of Cancer & Clinical Oncology, 1987, 23, 1209-1211.	0.7	93
38	Topoisomerase II enzymes and mutagenicity. Environmental and Molecular Mutagenesis, 1994, 24, 245-261.	2.2	90
39	5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent. Clinical Cancer Research, 2006, 12, 1776-1784.	7.0	90
40	Synthesis and antitumor activity of some indeno[1,2- b]quinoline-based bis carboxamides. Bioorganic and Medicinal Chemistry, 2000, 8, 977-984.	3.0	87
41	Synthesis and Cytotoxic Activity of 7-Oxo-7H-dibenz[f,ij]isoquinoline and 7-Oxo-7H-benzo[e]perimidine Derivatives. Journal of Medicinal Chemistry, 2001, 44, 2004-2014.	6.4	86
42	Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. Journal of Medicinal Chemistry, 1986, 29, 472-477.	6.4	83
43	DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. Journal of Medicinal Chemistry, 1990, 33, 1177-1186.	6.4	83
44	Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). European Journal of Cancer & Clinical Oncology, 1987, 23, 1047-1050.	0.7	82
45	Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer. Frontiers in Genetics, 2014, 5, 379.	2.3	76
46	Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biology and Therapy, 2011, 11, 938-946.	3.4	74
47	A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells. PLoS ONE, 2009, 4, e8461.	2.5	74
48	Comparison of in Vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. European Journal of Cancer & Clinical Oncology, 1986, 22, 655-662.	0.7	72
49	Effect of Flavone Acetic Acid on Lewis Lung Carcinoma: Evidence for an Indirect Effect1. Journal of the National Cancer Institute, 1988, 80, 241-245.	6.3	72
50	Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma. Cancer Research, 2006, 66, 6473-6476.	0.9	72
51	Structureâ^'Activity Relationships for Acridine-Substituted Analogues of the Mixed Topoisomerase I/II Inhibitor N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 1997, 40, 1919-1929.	6.4	70
52	Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. International Journal of Cancer, 2005, 116, 322-326.	5.1	70
53	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	1.1	66
54	Mechanisms of Action of DNA Intercalating Acridine-based Drugs: How Important are Contributions from Electron Transfer and Oxidative Stress?. Current Medicinal Chemistry, 2003, 10, 2643-2649.	2.4	65

#	Article	IF	Citations
55	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. International Journal of Pharmaceutics, 2008, 360, 115-121.	5.2	65
56	Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity. Journal of Medicinal Chemistry, 1987, 30, 658-663.	6.4	62
57	DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). Journal of Medicinal Chemistry, 1992, 35, 2983-2987.	6.4	62
58	Dicationic Bis(9-methylphenazine-1-carboxamides):Â Relationships between Biological Activity and Linker Chain Structure for a Series of Potent Topoisomerase Targeted Anticancer Drugs. Journal of Medicinal Chemistry, 2001, 44, 1407-1415.	6.4	62
59	Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. Journal of Medicinal Chemistry, 1991, 34, 2864-2870.	6.4	61
60	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anti-Cancer Drugs, 2002, 13, 15-28.	1.4	61
61	Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor Î± on Colon 38 tumours in mice. European Journal of Cancer & Clinical Oncology, 1989, 25, 263-269.	0.7	59
62	In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemotherapy and Pharmacology, 1993, 31, 401-406.	2.3	59
63	Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. European Journal of Cancer & Clinical Oncology, 1988, 24, 1783-1790.	0.7	57
64	Design of NDA Intercalators To Overcome Topoisomerase II-Mediated Multidurg Resistance. Journal of the National Cancer Institute, 1990, 82, 398-402.	6.3	57
65	DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. Journal of Medicinal Chemistry, 1990, 33, 3008-3014.	6.4	57
66	Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients. Clinical Cancer Research, 2004, 10, 5949-5956.	7.0	57
67	Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents. Journal of Medicinal Chemistry, 1988, 31, 774-779.	6.4	55
68	Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. Journal of Mathematical Biology, 2004, 49, 329-357.	1.9	55
69	Potential antitumor agents. 56. Minimal DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. Journal of Medicinal Chemistry, 1988, 31, 1048-1052.	6.4	54
70	Positioning of the Carboxamide Side Chain in 11-Oxo-11 H -indeno[1,2- b]quinolinecarboxamide Anticancer Agents: Effects on Cytotoxicity. Bioorganic and Medicinal Chemistry, 2001, 9, 445-452.	3.0	54
71	MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biology and Therapy, 2010, 9, 717-724.	3.4	54
72	Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model. Analytical Biochemistry, 2016, 515, 47-54.	2.4	54

#	Article	IF	Citations
73	Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Frontiers in Oncology, 2015, 5, 135.	2.8	52
74	Synthesis and Cytotoxic Activity of Carboxamide Derivatives of Benzo[b][1,6]naphthyridines. Journal of Medicinal Chemistry, 2003, 46, 1049-1054.	6.4	51
75	Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110Î± inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 7677-7687.	3.0	51
76	Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anti-Cancer Drugs, 2001, 12, 359-367.	1.4	50
77	Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 571-577.	2.5	50
78	Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug. Pharmaceutical Research, 2015, 32, 1451-1461.	3.5	49
79	Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemotherapy and Pharmacology, 2000, 45, 417-422.	2.3	48
80	DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. Journal of Medicinal Chemistry, 1990, 33, 3014-3019.	6.4	47
81	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. Journal of Drug Targeting, 2010, 18, 125-133.	4.4	46
82	Phase I study of the cytotoxic agent N â€Š-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 1999, 44, 39-44.	2.3	45
83	Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. International Journal of Molecular Sciences, 2017, 18, 1378.	4.1	45
84	Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	44
85	Ring-substituted 11-oxo-11 H -indeno[1,2- b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. Bioorganic and Medicinal Chemistry, 1999, 7, 2801-2809.	3.0	43
86	Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. PLoS ONE, 2015, 10, e0131400.	2.5	43
87	Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. Journal of Medicinal Chemistry, 1990, 33, 1375-1379.	6.4	42
88	5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Investigational New Drugs, 2002, 20, 281-295.	2.6	42
89	Modelling cell population growth with applications to cancer therapy in human tumour cell lines. Progress in Biophysics and Molecular Biology, 2004, 85, 353-368.	2.9	42
90	Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. Journal of Controlled Release, 2015, 203, 161-169.	9.9	42

#	Article	IF	Citations
91	Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1993, 33, 77-81.	2.3	41
92	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorganic and Medicinal Chemistry, 2005, 13, 1341-1355.	3.0	41
93	Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemotherapy and Pharmacology, 1999, 43, 323-330.	2.3	40
94	Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Frontiers in Genetics, 2013, 4, 66.	2.3	40
95	Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population. BioMed Research International, 2014, 2014, 1-7.	1.9	40
96	Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. Journal of Medicinal Chemistry, 1991, 34, 491-496.	6.4	39
97	Major Changes in Chromatin Condensation Suggest the Presence of an Apoptotic Pathway in Plant Cells. Experimental Cell Research, 1998, 241, 46-54.	2.6	39
98	Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opinion on Investigational Drugs, 2010, 19, 1413-1425.	4.1	39
99	The use of human cancer cell lines as a primary screening system for antineoplastic compounds. European Journal of Cancer & Clinical Oncology, 1984, 20, 947-954.	0.7	38
100	Selectivity of N-[2-(Dimethylamino)ethyl]acridine-4-carâ˜amide towards Lewis lung carcinoma and human tumour cell lines in vitro. European Journal of Cancer & Clinical Oncology, 1989, 25, 271-277.	0.7	37
101	Synthesis of Substituted Indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: Evaluation of Structureâ€“Activity Relationships for Cytotoxicity. Bioorganic and Medicinal Chemistry, 2000, 8, 2461-2466.	3.0	37
102	Modelling the flow of cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison. Bulletin of Mathematical Biology, 2005, 67, 815-830.	1.9	35
103	Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. Journal of Medicinal Chemistry, 1992, 35, 258-266.	6.4	34
104	Novel pyrazolo[1,5-a]pyridines as p110Î±-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. Bioorganic and Medicinal Chemistry, 2012, 20, 58-68.	3.0	34
105	Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clinica Chimica Acta, 2001, 314, 159-166.	1.1	33
106	Thiolytic cleavage of the anti-tumour compound 4â€²-(9-acridinylamino)-methanesulphon-m-anisidine (m-AMSA, NSC 156 303) in blood. Chemico-Biological Interactions, 1977, 18, 163-178.	4.0	32
107	Redox chemistry of the 9-anilinoacridine class of antitumor agents. Journal of Medicinal Chemistry, 1987, 30, 473-480.	6.4	32
108	Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 209, 57-62.	1.1	32

#	Article	IF	Citations
109	Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Frontiers in Oncology, 2017, 7, 184.	2.8	32
110	Thalidomide metabolites in mice and patients with multiple myeloma. Clinical Cancer Research, 2003, 9, 1680-8.	7.0	32
111	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemotherapy and Pharmacology, 1991, 28, 409-413.	2.3	31
112	Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemotherapy and Pharmacology, 2000, 46, 135-141.	2.3	30
113	Discovery of pyrazolo[1,5-a]pyridines as p110Î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 69-85.	3.0	30
114	Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity. Journal of Medicinal Chemistry, 1983, 26, 1625-1630.	6.4	29
115	The potential of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide]to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemotherapy and Pharmacology, 1997, 39, 424-430.	2.3	29
116	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. European Journal of Pharmaceutical Sciences, 2005, 24, 513-524.	4.0	29
117	Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 121-127.	1.6	29
118	Electron-Deficient DNA Intercalating Agents as Antitumor Drugs: Aza Analogs of the Experimental Clinical Agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 1994, 37, 593-597.	6.4	28
119	Metabolism of N ?-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 1999, 44, 51-58.	2.3	28
120	Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine. Journal of Medicinal Chemistry, 1984, 27, 363-367.	6.4	27
121	Mechanism of cytotoxicity of N -[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Cancer Chemotherapy and Pharmacology, 1999, 43, 302-308.	2.3	27
122	Potential of DMXAA combination therapy for solid tumors. Expert Review of Anticancer Therapy, 2002, 2, 593-603.	2.4	27
123	MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a â€œGenetic Switchâ€•Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Frontiers in Oncology, 2013, 3, 229.	2.8	27
124	Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell International, 2016, 16, 18.	4.1	27
125	The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival. PLoS ONE, 2011, 6, e26737.	2.5	27
126	DNA-directed alkylating agents. 4. 4-Anilinoquinoline-based minor groove directed aniline mustards. Journal of Medicinal Chemistry, 1991, 34, 1552-1560.	6.4	26

#	Article	IF	Citations
127	Induction of tumour necrosis factor and interferon-Î³ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochemical Pharmacology, 2004, 67, 937-945.	4.4	26
128	The Role of the Hippo Pathway in Melanocytes and Melanoma. Frontiers in Oncology, 2013, 3, 123.	2.8	26
129	Comparative studies of mutagenic, DNA binding and antileukaemic properties of 9-anilinoacridine derivatives and related compounds. Chemico-Biological Interactions, 1983, 44, 53-62.	4.0	25
130	Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. European Journal of Cancer & Clinical Oncology, 1989, 25, 1695-1701.	0.7	25
131	Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Frontiers in Oncology, 2013, 3, 225.	2.8	25
132	Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards. Bioorganic and Medicinal Chemistry, 1995, 3, 679-691.	3.0	24
133	Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives. Journal of Medicinal Chemistry, 1986, 29, 69-74.	6.4	23
134	Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochemical Pharmacology, 1992, 44, 192-195.	4.4	23
135	Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines. PLoS ONE, 2014, 9, e105792.	2.5	23
136	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. Frontiers in Oncology, 2014, 4, 221.	2.8	23
137	DNA-Binding Anticancer Drugs: One Target, Two Actions. Molecules, 2021, 26, 552.	3.8	23
138	Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. European Journal of Cancer & Clinical Oncology, 1983, 19, 1607-1613.	0.7	22
139	Potential antitumor agents. Part 38. 3-Substituted 5-carboxamido derivatives of amsacrine. Journal of Medicinal Chemistry, 1983, 26, 1619-1625.	6.4	22
140	Electron donor properties of the antitumour drug amsacrine as studied by fluorescence quenching of DNA-bound ethidium. Chemico-Biological Interactions, 1987, 62, 45-58.	4.0	22
141	Effect of flavone acetic acid (NSC 347 512) on splenic cytotoxic effector cells and their role in tumour necrosis. European Journal of Cancer & Clinical Oncology, 1989, 25, 821-828.	0.7	22
142	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. European Journal of Cancer & Clinical Oncology, 1991, 27, 1617-1620.	0.7	22
143	Plasma pharmacokinetics of Nâ€Š -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. Cancer Chemotherapy and Pharmacology, 1999, 44, 45-50.	2.3	22
144	Synthesis and cytotoxic activity of N -(2-Diethylamino)ethylcarboxamide and other derivatives of 10 H -Quindoline. Bioorganic and Medicinal Chemistry, 2002, 10, 2381-2386.	3.0	22

#	Article	IF	Citations
145	Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorganic and Medicinal Chemistry, 2005, 13, 3657-3665.	3.0	21
146	Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer, 2020, 20, 470.	2.6	21
147	Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. European Journal of Cancer & Clinical Oncology, 1990, 26, 586-589.	0.7	20
148	Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemotherapy and Pharmacology, 2007, 59, 661-669.	2.3	20
149	Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients. Clinical Cancer Research, 2008, 14, 2102-2110.	7.0	20
150	The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. Methods in Molecular Biology, 2016, 1395, 207-227.	0.9	20
151	Potential antitumor agents. 47. 3'-Methylamino analogs of amsacrine with in vivo solid tumor activity. Journal of Medicinal Chemistry, 1986, 29, 1769-1776.	6.4	19
152	The morphological effects of the antiâ€“tumor agents flavone acetic acid and 5,6â€“dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology, 1994, 26, 161-169.	0.6	19
153	In vivo effects of chlorophyllin on the antitumour agent cyclophosphamide. , 1997, 70, 84-89.		19
154	Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemotherapy and Pharmacology, 2002, 50, 186-192.	2.3	19
155	Induction of petite mutants in yeast by non-intercalative DNA-binding antitumour agents. European Journal of Cancer & Clinical Oncology, 1983, 19, 1575-1583.	0.7	18
156	Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast. Biochemical Pharmacology, 1986, 35, 4581-4584.	4.4	18
157	Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemotherapy and Pharmacology, 2001, 47, 491-497.	2.3	18
158	Phenazine-1-carboxamides: Structureâ€“cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain. Bioorganic and Medicinal Chemistry, 2006, 14, 1160-1168.	3.0	18
159	Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues. Biochemical Pharmacology, 1992, 43, 2401-2406.	4.4	17
160	Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 1992, 29, 475-479.	2.3	17
161	Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1992, 31, 151-155.	2.3	17
162	Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environmental and Molecular Mutagenesis, 1996, 27, 255-262.	2.2	17

#	Article	IF	Citations
163	PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Research, 2011, 21, 24-34.	1.2	17
164	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). European Journal of Medicinal Chemistry, 2013, 64, 137-147.	5.5	17
165	Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473, 528-535.	5.2	17
166	Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine. Journal of Medicinal Chemistry, 1982, 25, 1231-1235.	6.4	16
167	Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1988, 204, 207-217.	1.2	16
168	ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future Oncology, 2010, 6, 1537-1543.	2.4	16
169	Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Frontiers in Oncology, 2014, 3, 333.	2.8	16
170	Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. Frontiers in Oncology, 2018, 8, 425.	2.8	16
171	Potential antitumor agents. 52. Carbamate analogs of amsacrine with in vivo activity against multidrug-resistant P388 leukemia. Journal of Medicinal Chemistry, 1987, 30, 1576-1581.	6.4	15
172	Cytokinetic differences in the action ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemotherapy and Pharmacology, 1993, 32, 463-470.	2.3	15
173	Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases III± and Î². Cancer Chemotherapy and Pharmacology, 1999, 44, 275-282.	2.3	15
174	Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Investigational New Drugs, 2007, 25, 271-276.	2.6	15
175	Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: Comparison of microbial and mammalian systems. European Journal of Cancer & Clinical Oncology, 1989, 25, 255-261.	0.7	14
176	Induction of natural killer activity by Xanthenone analogues of flavone acetic acid: Relation with antitumour activity. European Journal of Cancer & Clinical Oncology, 1991, 27, 79-83.	0.7	14
177	Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemotherapy and Pharmacology, 2002, 49, 20-26.	2.3	14
178	Estimation of Radiation-Induced Interphase Cell Death in Cultures of Human Tumor Material and in Cell Lines. Oncology Research, 2003, 14, 297-304.	1.5	14
179	Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemotherapy and Pharmacology, 2008, 61, 497-502.	2.3	14
180	Centrosomal dysregulation in human metastatic melanoma cell lines. Cancer Genetics, 2011, 204, 477-485.	0.4	14

#	Article	IF	Citations
181	Preclinical Efficacy of Vascular Disrupting Agents in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2011, 12, 81-86.	2.6	14
182	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2017, 25, 5859-5874.	3.0	14
183	Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy. Drug Delivery, 2018, 25, 611-622.	5.7	14
184	Inverse correlation between bacterial frameshift mutagenicity and yeast mitochondrial effects of antitumour anilinoacridines. Chemico-Biological Interactions, 1985, 56, 145-155.	4.0	13
185	In vitro methods for screening agents with an indirect mechanism of antitumour activity: Xanthenone analogues of flavone acetic acid. European Journal of Cancer & Clinical Oncology, 1991, 27, 1684-1689.	0.7	13
186	Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures. Radiation Oncology Investigations, 1993, 1, 261-269.	0.9	13
187	Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemotherapy and Pharmacology, 2004, 53, 377-383.	2.3	13
188	The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemotherapy and Pharmacology, 2008, 62, 753-762.	2.3	13
189	The Genes of Life and Death: A Potential Role for Placentalâ€Specific Genes in Cancer. BioEssays, 2017, 39, 1700091.	2.5	13
190	Potential antitumor agents. 41. Analogs of amsacrine with electron-donor substituents in the anilino ring. Journal of Medicinal Chemistry, 1984, 27, 367-372.	6.4	12
191	Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity. Journal of Medicinal Chemistry, 1987, 30, 652-658.	6.4	12
192	Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 825-828.	1.9	12
193	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology, 2003, 65, 109-120.	4.4	12
194	Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Investigational New Drugs, 2011, 29, 1102-1110.	2.6	12
195	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. MedChemComm, 2014, 5, 41-46.	3.4	12
196	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2019, 27, 1529-1545.	3.0	12
197	Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clinical Cancer Research, 2003, 9, 6545-50.	7.0	12
198	Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiae. European Journal of Cancer & Clinical Oncology, 1990, 26, 55-60.	0.7	11

#	Article	IF	Citations
199	Novel Strategies for Overcoming Multidrug Resistance in Cancer. BioDrugs, 2002, 16, 97-103.	4.6	11
200	Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Investigational New Drugs, 2012, 30, 2103-2112.	2.6	11
201	Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. Clinical Investigation, 2012, 2, 985-993.	0.0	11
202	Mathematical Determination of Cell Population Doubling Times for Multiple Cell Lines. Bulletin of Mathematical Biology, 2012, 74, 2510-2534.	1.9	11
203	Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate. Cell Calcium, 2016, 60, 384-395.	2.4	11
204	Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance. Methods in Molecular Biology, 2016, 1395, 19-37.	0.9	11
205	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. Oncology and Therapy, 2021, 9, 541-556.	2.6	11
206	Retrotransposon Hypomethylation in Melanoma and Expression of a Placenta-Specific Gene. PLoS ONE, 2014, 9, e95840.	2.5	11
207	Differential growth inhibition of cultured mammalian cells: Comparison of clinical antitumour agents and amsacrine derivatives. European Journal of Cancer & Clinical Oncology, 1984, 20, 383-389.	0.7	10
208	Hyporesponsiveness of macrophages from (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512). European Journal of Cancer & Clinical Oncology, 1989, 25, 1513-1515.	0.7	10
209	Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent. European Journal of Cancer & Clinical Oncology, 1990, 26, 709-714.	0.7	10
210	Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 87-97.	2.3	10
211	Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA;) Tj ETQq1 1 0.784314 rgBT /Over	2.6	10
212	Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemotherapy and Pharmacology, 2010, 65, 1145-1152.	2.3	10
213	A Comparison of the Ability of DMXAA and Xanthenone Analogues to Activate NF-Î²B in Murine and Human Cell Lines. Oncology Research, 2005, 15, 351-364.	1.5	10
214	NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Research, 2007, 27, 327-34.	1.1	10
215	The immunological status of mice during the generation of cyclophosphamide-induced tolerance. Cellular Immunology, 1976, 25, 217-227.	3.0	9
216	Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine. Journal of Medicinal Chemistry, 1984, 27, 1053-1056.	6.4	9

#	Article	IF	Citations
217	Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of Amsacrine. European Journal of Cancer & Clinical Oncology, 1987, 23, 607-613.	0.7	9
218	Localization of a nonintercalative DNA binding antitumour drug in mitochondria: Relationship to multidrug resistance. European Journal of Cancer & Clinical Oncology, 1989, 25, 1287-1293.	0.7	9
219	Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid. European Journal of Cancer & Clinical Oncology, 1989, 25, 1061-1065.	0.7	9
220	Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Applied Radiation and Isotopes, 1997, 48, 487-492.	1.5	9
221	Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. Journal of Theoretical Biology, 2009, 260, 563-571.	1.7	9
222	The paradox of cancer cell apoptosis. Frontiers in Bioscience - Landmark, 2011, 16, 1759.	3.0	9
223	Therapeutic reactivation of mutant p53 protein by quinazoline derivatives. Investigational New Drugs, 2012, 30, 2035-2045.	2.6	9
224	Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling. Bioorganic and Medicinal Chemistry, 2015, 23, 3796-3808.	3.0	9
225	Improving drug retention in liposomes by aging with the aid of glucose. International Journal of Pharmaceutics, 2016, 505, 194-203.	5.2	9
226	PIK3CAâ€mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. Pigment Cell and Melanoma Research, 2017, 30, 353-367.	3.3	9
227	Novel pyrazolo[1,5- a]pyridines with improved aqueous solubility as p110Î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 187-190.	2.2	9
228	Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. Pigment Cell and Melanoma Research, 2021, 34, 136-143.	3.3	9
229	Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid. Cancer Chemotherapy and Pharmacology, 1991, 28, 414-419.	2.3	8
230	Selective antitumour activity of metal complexes of bidentate pyridylphosphines. Journal of Inorganic Biochemistry, 1997, 67, 154.	3.5	8
231	Development and validation of a liquid chromatographyâ€“mass spectrometry (LCâ€“MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN) Tj ETQq1 1 0.784314 rgBT /O 2008, 875, 368-372.	2.3	8
232	Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2012, 70, 151-160.	2.3	8
233	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Cancer Chemotherapy and Pharmacology, 2014, 74, 25-35.	2.3	8
234	A comparison of the requirements for antitumour activity and antibacteriophage lambda activity for a series of non-intercalative DNA-binding agents. European Journal of Cancer & Clinical Oncology, 1982, 18, 271-279.	0.7	7

#	Article	IF	Citations
235	Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells. European Journal of Cancer & Clinical Oncology, 1990, 26, 49-54.	0.7	7
236	DNA Binding of the Nonintercalative Ligands SN-6132, SN-6131 and SN-6113: Minor Variations of the Ligand Structure May Cause Changes in the Base Pair Preference. Journal of Biomolecular Structure and Dynamics, 1992, 10, 551-564.	3.5	7
237	A rapid LCâ€“MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: Application to in vivo pharmacokinetic and lipophilicity studies in drug development. Journal of Pharmaceutical and Biomedical Analysis, 2012, 63, 9-16.	2.8	7
238	9-anilinoacridines: Novel compounds active against herpes simplex virus. Chemico-Biological Interactions, 1985, 54, 377-382.	4.0	6
239	Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells. European Journal of Cancer & Clinical Oncology, 1988, 24, 205-210.	0.7	6
240	Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues. Biochemical Pharmacology, 1992, 43, 386-389.	4.4	6
241	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology, 2003, 65, 1853-1865.	4.4	6
242	The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs. Expert Opinion on Drug Discovery, 2008, 3, 153-161.	5.0	6
243	Genome-wide DNA methylation and RNA expression differences correlate with invasiveness in melanoma cell lines. Epigenomics, 2021, 13, 577-598.	2.1	6
244	Determination of the activation spectrum of aluminium phthalocyanine chloride against cultured meningioma cells using a tunable laser. Journal of Clinical Neuroscience, 1996, 3, 252-256.	1.5	5
245	Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 386-390.	2.8	5
246	In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma. Investigational New Drugs, 2011, 29, 1504-1510.	2.6	5
247	Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice. Frontiers in Oncology, 2014, 4, 310.	2.8	5
248	Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: Relevance to clinical trials. European Journal of Cancer & Clinical Oncology, 1988, 24, 211-218.	0.7	4
249	Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. Cancer Chemotherapy and Pharmacology, 2013, 72, 1013-1022.	2.3	4
250	The ubiquitinâ€“proteasome system is inhibited by p53 protein expression in human ovarian cancer cells. Cancer Letters, 2010, 294, 82-90.	7.2	3
251	Do Negative Feedback Oscillations Drive Variations in the Length of the Tumor Cell Division Cycle?. Oncology Research, 2005, 15, 291-294.	1.5	3
252	Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. European Journal of Cancer & Clinical Oncology, 1985, 21, 1337-1341.	0.7	2

#	Article	IF	Citations
253	The relationship between lipophilic-hydrophilic balance, uptake and anti-bacteriophage lambda activity of experimental anti-tumour bisquaternary salts. Chemico-Biological Interactions, 1988, 65, 85-95.	4.0	2
254	Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1991, 264, 231-234.	1.1	2
255	SOX2OT Long Noncoding RNA Is Regulated by the UPR in Oestrogen Receptor-Positive Breast Cancer. Sci, 2021, 3, 26.	3.0	2
256	Inhibition of Tumor Blood Flow. , 2000, 25, 133-157.		1
257	SOX2OT Long Noncoding RNA Is Regulated by the UPR in Oestrogen Receptor-Positive Breast Cancer. Sci, 2020, 2, 24.	3.0	1
258	Cultures of Surgical Material from Lung Cancers: A Kinetic Approach. , 2003, 74, 527-544.		1
259	Mutagenic potency and drug structure in some experimental anti-cancer drugs. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1980, 74, 420.	0.4	0
260	Sequence-specific interactions of minor groove binders with the 154 base pair hindlll-rsal restriction fragment of cDNA of the human tau 40 protein involved in pathology of alzheimer's disease. IUBMB Life, 1997, 41, 143-152.	3.4	0
261	Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation, 2014, 4, 1113-1122.	0.0	0
262	Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemotherapy and Pharmacology, 1994, 34, 159-165.	2.3	0
263	Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemotherapy and Pharmacology, 1994, 35, 153-160.	2.3	0